We earlier demonstrated TSP2 as a potential serum biomarker for clinical application in nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis due to its strong correlations with hepatocellular ballooning, NAFLD activity score, and fibrosis stage in biopsy-proven NAFLD cases11. Here, THBS2 is linked to metabolic dysfunction-associated steatotic liver disease.